Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer

Home > Science Hub > Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer
Back to the list

April 12, 2022

Dirix L et al. Breast Cancer Research and Treatments, 2022

Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer

Download Publication

You might also be interested by

Infographics

Next-Generation Flow Cytometry Analysis with CellEngine™

January 31, 2023

Immune Monitoring

More info

Brochures

Cutting-Edge Digital and AI-Powered Pathology Services

January 30, 2023

More info

Web News

Simcere Diagnostics and CellCarta Enter Into Strategic Partnership

December 20, 2022

More info

CellTalk

Demystifying HGRAC – A Must When Running Clinical Trials in China

November 14, 2022

More info